We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+30.88%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$149M
AUM Growth
+$1.61M
(+1.1%)
Cap. Flow
+$7.75M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
54.08%
Holding
54
New
19
Increased
8
Reduced
16
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$7.23M |
| 2 |
Taysha Gene Therapies
TSHA
|
+$7.15M |
| 3 |
Replimune Group
REPL
|
+$2.95M |
| 4 |
HLVX
HilleVax
HLVX
|
+$2.92M |
| 5 |
Alkermes
ALKS
|
+$2.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$5.17M |
| 2 |
argenx
ARGX
|
+$4.9M |
| 3 |
Clene
CLNN
|
+$3.73M |
| 4 |
GH Research
GHRS
|
+$2.9M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$2.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.72% |
| 2 | Financials | 0.33% |
| 3 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Taysha Gene Therapies
TSHA
$1.66B
| $12.1M | 8.11% |
+3,827,926
| New | +$7.15M |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $9.3M | 6.23% |
244,484
-53,112
| -18% | -$2.33M |
|
|
WHWK
3
Whitehawk Therapeutics
WHWK
$196M
| $8.95M | 6% |
1,849,402
| – | – |
|
4
Praxis Precision Medicines
PRAX
$8.52B
| $7.67M | 5.14% |
299,000
+15,667
| +6% | +$296K |
|
|
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $7.65M | 5.13% |
+344,571
| New | +$7.23M |
|
6
CALL
Sarepta Therapeutics
SRPT
$1.68B
| $7.58M | 5.08% |
+550
| New | +$62.2K |
|
7
Rocket Pharmaceuticals
RCKT
$372M
| $7.42M | 4.97% |
362,000
+55,806
| +18% | +$1.01M |
|
|
VTYX
8
DELISTED
Ventyx Biosciences
VTYX
| $7.13M | 4.78% |
205,377
+58,059
| +39% | +$2.01M |
|
9
Disc Medicine
IRON
$2.93B
| $6.49M | 4.35% |
138,198
-1,302
| -0.9% | -$65.1K |
|
10
Kura Oncology
KURA
$816M
| $6.4M | 4.29% |
702,093
-7,025
| -1% | -$71.3K |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $6.23M | 4.18% |
418,000
-12,000
| -3% | -$159K |
|
12
Vaxcyte
PCVX
$7.73B
| $6.17M | 4.13% |
121,022
-1,144
| -0.9% | -$56.4K |
|
13
Immunovant
IMVT
$7.91B
| $4.95M | 3.32% |
129,000
-12,755
| -9% | -$288K |
|
14
Syndax Pharmaceuticals
SNDX
$1.7B
| $4.31M | 2.89% |
297,035
-2,806
| -0.9% | -$53.1K |
|
|
HLVX
15
DELISTED
HilleVax
HLVX
| $3.64M | 2.44% |
270,319
+207,241
| +329% | +$2.92M |
|
|
16
Alkermes
ALKS
$8.31B
| $3.54M | 2.37% |
126,500
+81,811
| +183% | +$2.4M |
|
17
Viridian Therapeutics
VRDN
$2.13B
| $3.44M | 2.31% |
224,339
-368
| -0.2% | -$7.02K |
|
18
Celldex Therapeutics
CLDX
$2.96B
| $3.37M | 2.26% |
122,341
-2
| -0% | -$63 |
|
19
Crinetics Pharmaceuticals
CRNX
$8.87B
| $2.8M | 1.87% |
+94,000
| New | +$1.94M |
|
|
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
| $2.79M | 1.87% |
555,260
-414,740
| -43% | -$2.63M |
|
|
21
Replimune Group
REPL
$1B
| $2.57M | 1.72% |
+150,000
| New | +$2.95M |
|
22
EyePoint Inc
EYPT
$1.04B
| $2.4M | 1.61% |
300,128
-81,872
| -21% | -$898K |
|
|
IMA
23
ImageneBio Inc
IMA
$64.2M
| $2.39M | 1.6% |
45,918
-582
| -1% | -$35K |
|
|
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
| $2.09M | 1.4% |
+323,349
| New | +$2.21M |
|
25
Olema Pharmaceuticals
OLMA
$985M
| $1.89M | 1.27% |
153,007
+47,193
| +45% | +$481K |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q3 2023 Portfolio in Review
As of Q3 2023, Acuta Capital Partners held 54 positions worth $149M, up 1.1% from $148M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Acuta Capital Partners deployed $7.75M of net new capital in Q3 2023, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was RayzeBio, Inc. Common Stock: 344,571 shares worth $7.65M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 97% a quarter earlier, followed by Financials and Consumer Staples.
On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.63M trimmed.
- Acuta Capital Partners's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 344,571 shares worth $7.65M.
- Acuta Capital Partners added most to HilleVax in Q3 2023, an estimated $2.92M increase.
- Acuta Capital Partners's biggest Q3 2023 reduction was Terns Pharmaceuticals, cutting an estimated $2.63M.
- Acuta Capital Partners fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.17M.
- Acuta Capital Partners's ten largest holdings make up 54% of its $149M portfolio in Q3 2023.
- Acuta Capital Partners opened 19 new positions and closed 8 in Q3 2023.
- Acuta Capital Partners's portfolio value rose 1.1% quarter-over-quarter to $149M.
Based on Acuta Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.